NKTR today
$37.97-$0.47 (-1.23%)close Nov 12, 2026Trend
DailyDowntrend (confirmed)
4 hourExpanding
1 hourDescending Triangle
15 minBearish
5 minSymmetric Triangle
Daily trend turns up above $42.38
Key levels
Resistance$42.62
Resistance$40.35
Support$36.66
Support$34.47
Latest news & SEC filings
AnalystUBS starts Nektar Therapeutics coverage with Neutral rating, $53 price target
All NKTR news →About Nektar Therapeutics
Nektar Therapeutics is a clinical-stage biopharmaceutical company that discovers and develops immunomodulatory medicines. Its pipeline targets autoimmune diseases and cancer, with lead candidates including rezpegaldesleukin, NKTR-0165/0166, and NKTR-255. The company operates in the United States and relies on third-party manufacturers and collaborators for development and supply.
Based on the company's 10-K filed Mar 13, 2026.
Nasdaq · Healthcare
NEKTAR THERAPEUTICS (NKTR)
What Is the Price Target for NKTR?
SEPT Low Target
$130.05
SEPT Mid Target
$153.00
SEPT High Target
$175.95
Analyst Consensus
$153.00
Is NKTR a Buy or Sell Right Now?
Thesis
- •Revenue growing -43.9% YoY with DECLINING trend — consistent growth.
AI-Powered Trading Signals
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for NKTR.
Start Free Trial →Is NKTR Overvalued or Undervalued?
Valuation Verdict
UNDERVALUED
Methods Used
P/B, Analyst Consensus
Fair Value
$131.94
2
Moat Score
NONE
2/9
Piotroski Score
-17.2
Altman Z-Score
What Is Smart Money Doing with NKTR?
Insider Signal
SELLING
0 buys / 5 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
ACCUMULATING
Short Squeeze Risk
HIGH
Signal: HIGH_SHORT_INTEREST
Recent Insider Activity
| Name | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
| WHITFIELD ROY A | director | Buy | 2,000 | - | Sep 23, 2026 |
| GREER R SCOTT | director | Buy | 2,000 | - | Sep 23, 2026 |
| CHESS ROBERT | director | Buy | 2,000 | - | Sep 23, 2026 |
| Brainard Diana | director | Buy | 2,000 | - | Sep 23, 2026 |
| Ajer Jeffrey Robert | director | Buy | 2,000 | - | Sep 23, 2026 |
| Zalevsky Jonathan | officer | Sale | 199 | $13K | May 19, 2026 |
| ROBIN HOWARD W | director officer | Sale | 444 | $29K | May 19, 2026 |
Track Smart Money Across 4,000+ Stocks
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →NKTR Growth Story
Revenue YoY
-43.9%
3yr Revenue CAGR
-15.7%
EPS Growth YoY
-12.1%
FCF Growth YoY
-17.8%
Revenue Trend
DECLINING
Dark Pool Trades for NKTR
PREVIEWSEPT Investing tracks real-time dark pool institutional trades for NKTR, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 14:47:41 | $37.37 | 1,000 | $$37K | SELL |
| 14:41:40 | $37.61 | 1,900 | $$71K | SELL |
| 14:40:18 | $37.45 | 1,000 | $$37K | SELL |
| 14:38:58 | $37.52 | 1,000 | $$38K | SELL |
| 14:37:21 | $37.27 | 2,000 | $$75K | BUY |
5 dark pool trades shown · $$258K preview volume
Real-time institutional flow, block trades, and net positioning
Full AI Research Report
SEPT's Trading AI has generated a free, downloadable PDF research report for NEKTAR THERAPEUTICS (NKTR) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (1 articles analyzed), and SEC filing intelligence...
AI-Powered Trading Signals.
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →NKTR — frequently asked questions
What is NKTR stock price today?
NEKTAR THERAPEUTICS (NKTR) is at $37.97, down 1.23% (-$0.47) at the Nov 12, 2026 close.
Why is NKTR stock moving today?
Latest NKTR news — Oct 12, 2026: UBS starts Nektar Therapeutics coverage with Neutral rating, $53 price target
What is the NKTR price target?
The average analyst price target for NKTR is $153.00, ranging from $50 to $192, based on 9 analysts. Latest: Leerink Partners initiates on Oct 12, 2026.
What do analysts rate NKTR?
Analyst ratings for NKTR: 0 Buy, 17 Hold, 0 Sell — consensus Hold.
Did NKTR beat earnings?
NKTR last reported on Aug 13, 2026: EPS -$1.23 vs -$1.97 expected — a beat of 37.6%.
Does NKTR pay a dividend?
NKTR does not currently pay a dividend.
What are NKTR support and resistance levels?
Support: $36.66, $34.47, $29.70. Resistance: $40.35, $42.62, $45.34.
What are insiders doing with NKTR?
Insider activity: SELLING, 0 buys and 5 sells in the last 90 days.
What is the latest news on NKTR?
Oct 12, 2026: UBS starts Nektar Therapeutics coverage with Neutral rating, $53 price target